Invesco Biotechnology & Genome ETF(PBE · ETF)
ETF quote, holdings, sector allocation, technicals, and options analytics.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $67.69 – $98.82
- YTD
- +18.11%
- IV Rank (30D)
- 17.47
- Straddle Price
- $4.30
Invesco Biotechnology & Genome ETF (PBE) ETF
- Exchange
- ARCX
- Inception
- 2005-06-23
- Has Options
- Yes
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-09-21 | 2026-09-25 | $0.0187 | CD |
| 2026-06-22 | 2026-06-26 | $0.8106 | CD |
| 2026-03-23 | 2026-03-27 | $0.0824 | CD |
| 2025-12-22 | 2025-12-26 | $0.4197 | CD |
| 2025-09-22 | 2025-09-26 | $0.2341 | CD |
| 2025-06-23 | 2025-06-27 | $0.1305 | CD |
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| NTRA | Natera Inc | 5.95% | Equity (US) | US |
| ILMN | Illumina Inc | 5.82% | Equity (US) | US |
| BIIB | Biogen Inc | 5.28% | Equity (US) | US |
| GILD | Gilead Sciences Inc | 5.24% | Equity (US) | US |
| REGN | Regeneron Pharmaceuticals Inc | 4.93% | Equity (US) | US |
| VRTX | Vertex Pharmaceuticals Inc | 4.79% | Equity (US) | US |
| RPRX | Royalty Pharma PLC | 4.76% | Equity (US) | — |
| AMGN | Amgen Inc | 4.71% | Equity (US) | US |
| MRNA | Moderna Inc | 3.20% | Equity (US) | US |
| NVAX | Novavax Inc | 3.12% | Equity (US) | US |
| HALO | Halozyme Therapeutics Inc | 2.87% | Equity (US) | US |
| RGEN | Repligen Corp | 2.84% | Equity (US) | US |
| TGTX | TG Therapeutics Inc | 2.82% | Equity (US) | US |
| SRPT | Sarepta Therapeutics Inc | 2.80% | Equity (US) | US |
| QGEN | QIAGEN NV | 2.80% | Equity (US) | — |
| EXEL | Exelixis Inc | 2.80% | Equity (US) | US |
| VCYT | Veracyte Inc | 2.78% | Equity (US) | US |
| INCY | Incyte Corp | 2.69% | Equity (US) | US |
| UTHR | United Therapeutics Corp | 2.64% | Equity (US) | US |
| BMRN | BioMarin Pharmaceutical Inc | 2.63% | Equity (US) | US |
| PTGX | Protagonist Therapeutics Inc | 2.57% | Equity (US) | US |
| ARDX | Ardelyx Inc | 2.57% | Equity (US) | US |
| NBIX | Neurocrine Biosciences Inc | 2.54% | Equity (US) | US |
| VCEL | Vericel Corp | 2.51% | Equity (US) | US |
| BCRX | BioCryst Pharmaceuticals Inc | 2.44% | Equity (US) | US |
| ANAB | AnaptysBio Inc | 2.43% | Equity (US) | US |
| LEGN | Legend Biotech Corp | 2.42% | Cash/Money Market | — |
| PTCT | PTC Therapeutics Inc | 2.37% | Equity (US) | US |
| ACAD | ACADIA Pharmaceuticals Inc | 2.33% | Equity (US) | US |
| COLL | Collegium Pharmaceutical Inc | 2.28% | Equity (US) | US |
| AGPXX | Invesco Government & Agency Portfolio | 0.07% | Cash/Money Market | — |
| USD | CASH & EQUIVALENTS | 0.00% | Other | US |
| — | SECURITIES LENDING - BNYM | 0.00% | Cash/Money Market | — |
| Category | Weight | Value | Positions |
|---|---|---|---|
| Short-term investment | 14.17% | $37.3M | 3 |
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -0.10% | 6 |
| Feb | -1.32% | 6 |
| Mar | -2.15% | 6 |
| Apr | -2.99% | 6 |
| May | +1.32% | 6 |
| Jun | +3.28% | 6 |
| Jul | +3.13% | 6 |
| Aug | +2.42% | 6 |
| Sep | -3.22% | 6 |
| Oct | +1.80% | 5 |
| Nov | +3.23% | 5 |
| Dec | +0.86% | 5 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Here is a comprehensive stock analysis report for PBE (Invesco Biotechnology & Genome ETF) based on the provided technical indicators, options metrics, beta analysis, market data, and recent news headlines.
Executive Summary
Overall Assessment: NEUTRAL with confidence level 6/10
Key Drivers:
- Bullish MACD signal indicating a trend reversal
- RSI neutral at 58.27, suggesting no overbought or oversold conditions
Primary Risks:
- Volatility regime indicates low volatility - stock moves less than market (Stock Volatility: 0.19)
- Beta of 0.60 suggests PBE is relatively defensive compared to the broader market
Investment Thesis: PBE's recent trend reversal and neutral RSI suggest a balanced risk-reward profile. However, the low volatility regime and defensive beta may limit potential upside.
Recent News Sentiment Impact: NEUTRAL
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Bullish
- Medium-term (1-3 months): Neutral
- Long-term (3-12 months): Bearish
Support/Resistance Levels: PBE's recent high at $100.14 provides immediate resistance, while the 20-day SMA at $94.92 acts as support.
Momentum Signals:
- RSI: 58.27 - neutral
- MACD: Bullish signal above signal line (1.97 / 0.10)
- Bollinger Bands: Neutral signal with no significant band breaches
Volume Analysis: PBE's volume SMA 20 at 58340.30 indicates a relatively stable trading environment.
News & Sentiment Analysis
Recent Headlines Summary: 6 recent news headlines all have neutral sentiment, discussing PBE as a health care ETF or comparing it to other biotech ETFs (VHT vs. PBE).
Sentiment Assessment: NEUTRAL
Catalyst Identification: No specific catalysts identified in recent news headlines.
Market Narrative: PBE's market narrative remains neutral due to the lack of significant news sentiment, which does not strongly contradict technical signals.
Risk & Volatility Assessment
Beta Interpretation: PBE's beta of 0.60 indicates a relatively defensive position compared to the broader market.
Volatility Regime: Low volatility regime suggests PBE is less likely to experience large price swings.
Options Market Signals: IV rank at 92.1% (high) shows historical volatility, while the current IV at 66.7% and expected move at $4.92 indicate a relatively calm options market.
Downside Protection: Support levels at 20-day SMA ($94.92) and Bollinger Bands provide some downside protection.
Market Context & Positioning
Sector Performance: PBE's health care sector performance is neutral, moving in line with the broader market.
Institutional Activity: No significant institutional activity flags are present.
Correlation Analysis: PBE's correlation with SPY at 0.40 indicates a relatively low relationship between the two assets.
Relative Valuation: PBE trades within its historical range, indicating no significant relative undervaluation or overvaluation.
Key Levels & Action Items
Critical Price Levels:
- Resistance: $100.14
- Support: $94.92
Breakout/Breakdown Levels:
- Breakout above $100.14 would suggest a strong bullish trend
- Breakdown below $94.92 could indicate a bearish reversal
Time-Sensitive Catalysts: No specific catalysts identified in recent news headlines.
Risk Management: Stop-loss levels should be set around $96.51, with position sizing considerations based on the expected move of $4.92.
Please let me know if you would like me to revise or expand this analysis in any way!
- IV Rank (30D)
- 17.47
- IV Rank (7D)
- 17.47
- Avg IV
- 30.5%
- Straddle (30D)
- $4.30
- Straddle (7D)
- $4.30
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
- Beta (1Y vs SPY)
- 0.64
- Correlation (SPY)
- 43.6%
- R²
- 0.19
- Ann. Volatility
- 19.0%
- SPY Volatility
- 13.0%
Low volatility - stock moves less than market
Click any bar to view the full quote for that stock.
| Symbol | Name | Weight % | Price | 1 Day | 1 Week | 1 Month |
|---|